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1. Introduction 
Medullary thyroid cancer (MTC) occurs in less than 1% of thyroid nodules and accounts for 
5-10% of thyroid malignancies. It is a well-differentiated neuroendocrine carcinoma arising 
from parafollicular calcitonin-producing cells (C-cells) of the thyroid gland and is associated 
with elevated serum calcitonin levels. Among well-differentiated thyroid carcinomas, MTC 
is the most aggressive, with survival rates of 40-50% at 10 years (American Thyroid 
Association [ATA] Guidelines Task Force et al., 2009; Leboulleux et al., 2004). In about 20-
25% of cases, MTC can be part of an autosomal dominant inherited cancer syndrome called 
Multiple Endocrine Neoplasia type 2 (MEN2), caused by activating germline mutations of 
the RET proto-oncogene, where this tumor is isolated (Familial MTC – FMTC) or is 
associated to other tumors (parathyroid adenoma, pheochromocytoma and cutaneous lichen 
amyloidosis in MEN2A; pheochromocytoma, mucosal and intestinal ganglioneuromatosis, 
marfanoid habitus in MEN2B). In the remaining 75-80% of cases MTC is sporadic (ATA 
Guidelines Task Force et al., 2009; Brandi et al., 2001; Leboulleux et al., 2004). Depending on 
the type of the genetic syndrome, clinical features, therapeutic approaches and prognosis of 
MTC are very different (Brandi et al., 2001). 
Calcitonin is a small peptide secreted by C-cells. It is the most specific and sensitive marker of 
MTC in patients with one or more thyroid nodules, useful in the diagnosis and follow-up of 
this tumor (ATA Guidelines Task Force et al., 2009; Leboulleux et al., 2004). High serum 
calcitonin levels are physiological in neonates, followed by an age-related decline from birth to 
about 1 year of age (Leboulleux et al., 2004). Elevated basal serum calcitonin levels are found in 
subjects with C-cells hyperplasia (CCH) or MTC. Anyway, in some cases it is possible to 
observe false positive or false negative for serum calcitonin levels in adult individuals.  
After excluding conditions that may cause falsely positive high levels of calcitonin, it is 
necessary to exclude tumors associated to ectopic production of calcitonin, which may 
represent up to 15% of cases (Pacini et al., 2010; Toledo et al., 2009). 
Another tumor marker used in the follow-up of MTC is carcino-embryonic antigen (CEA), a 
cytosolic enzyme which is not a specific biomarker for MTC being generally expressed by 
many endocrine and non-endocrine tumors. In MTC, CEA is considered to have lower 
diagnostic accuracy than calcitonin (Meijer et al., 2010). There is no close relationship 
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between serum levels of CEA, that are normal in patients with early stage MTC, and 
calcitonin.   
Pentagastrin stimulation test for calcitonin is the most widely used test for calcitonin 
secretion, useful to distinguish normal C-cells from pathological C-cells (Leboulleux et al., 
2004; Milone et al., 2010; Pacini et al., 2010).  
CCH and early-stage MTC are often difficult to distinguish on routine biochemical and 
histological examination. This differentiation is very important for therapy and for 
prognosis. 
If the diagnosis of MTC needs to be always confirmed by histology, by a clinical and 
biochemical point of view, pentagastrin stimulation test, immunocytochemistry for 
calcitonin and calcitonin measurement in wash-out fluid from fine-needle aspiration of 
suspicious thyroid nodules may reliably indicate this diagnosis. 
Primary treatment of both hereditary and sporadic MTC is total thyroidectomy with lymph 
node dissection, with the intention of remove all neoplastic tissue present in the neck 
(Leboulleux et al., 2004).  
The postoperative follow-up of patients with MTC should be performed to early identify 
recovery or persistence/relapse of MTC in patients with elevated concentrations of 
biochemical markers after surgery. 
1.1 Embryogenesis of C-cells and pathogenesis of MTC  
Parafollicular calcitonin-producing cells (C-cells) arise from the neural crest and have a 
common origin with the adrenal medullary chromaffin cells, enterochromaffin cells, 
pituitary corticotrophs and melanotrophs, and islet cells. This entire series of cells was 
included under the descriptive term APUD cells by Pearse (Hazard, 1977). During the 
embryonic life C-cells migrate forward into the thyroid gland. The thyroid should be looked 
upon as a double gland with two separate types of peptide-producing cells. C-cells account 
less than 1% of thyroid cells, are located inside the thyroid follicles and are most numerous 
at the junction of the upper third and the lower two-thirds of the thyroid lobes (Leboulleux 
et al., 2004).  
Thyroid C-cells differ from solid cell nests (SCN) of the thyroid gland. They are two thyroid 
specific cell type with a common  embryological origin in the ultimobranchial body but with 
different physiological roles. SCN are found in about 5-60% of human thyroid gland and 
comprise compact spindle or polygonal cells with a strong and diffuse immunostaining for 
cytokeratin, galectin-3 (GAL-3) and CEA and rarely for calcitonin. In contrast, normal and 
hyperplastic C-cells express both calcitonin and CEA but not GAL-3 while malignant C-cells 
forming MTC are positive for calcitonin, CEA and GAL-3 immunostaining. SCN are often 
found in both normal and pathological thyroid tissue and they are not related to the presence 
of thyroid disorder (Faggiano et al., 2003).  
GAL-3 is a β-galactoside-binding protein, localized predominantly in the cytoplasm, that 
plays a role in various processes such as cell adhesion, growth and neoplastic 
transformation. In epithelial thyroid tumors, GAL-3 immunostaining is positive in 
malignant tumors but negative in benign lesions. GAL-3 immunostaining is also a 
reliable marker of malignancy in patients with C-cells disease and its use may have 
clinically relevant prognostic and therapeutic implications (Faggiano et al., 2002)  
(Figure 1). 
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Fig. 1. Expression of calcitonin (CT), CEA and GAL-3 in medullary thyroid cancer (MTC) 
and C-cells hyperplasia (CCH). Photos a, c, e, g represent a MTC case: CT, CEA and GAL-3 
are diffusely expressed in tumor tissue at the cytoplasmatic level. Some tumor cells also 
display GAL-3 positivity at the nuclear level (black arrows). The specificity of anti-GAL-3 
antibodies is demonstrated by negativity in control sections (CS) of the same tumor. Photos 
b, d, f represent a CCH case: CT and CEA are strongly positive and GAL-3 is negative in 
large C-cells (from Faggiano et al., 2002).   
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CCH is defined as the presence of at least three fields containing more than or equal 50 C-
cells in a single low-power field (magnification of x 100) (Santesanio et al., 1997). The 
prototypic histologic features of MTC are sheets, packets or irregular islands of polygonal or 
plump spindly cells traversed by small fibrovascular septa (Hazard, 1997). MTC is defined 
by the presence of fibrous and/or amyloid stroma between C-cells, infiltration of interstitial 
tissue by C-cells and coalescence of hyperplastic C-cells nodules (Faggiano et al.,  2002; 
Faggiano et al., 2003).  
MTC cells typically produce an early biochemical signal that consists of hypersecretion of 
calcitonin. Calcitonin and CEA are expressed in hyperplastic and malignant C-cells 
(Leboulleux et al., 2004). 
In all CCH and MTC there is a positive immunohistochemical staining for calcitonin and 
CEA. Mixed MTC are uncommon and are characterized by the combination of C-cells and 
follicular features (Leboulleux et al., 2004). 
Sporadic C-cells hyperplasia differs from C-cells hyperplasia associated to hereditary MTC 
syndromes. While the first one, in fact, is usually benign and associated with much less, is 
any, malignant potential, the latter is generally considered a precancerous condition in the 
familial MTC where there is a progression from normal C-cells to CCH, micro-MTC and 
clinical MTC (Leboulleux et al., 2004; Milone et al., 2010; Perry et al., 1996). Sporadic MTC is 
usually unifocal and represented by a unique tumor nodule while familial MTC appears 
bilateral and multicentric, often with multifocal disease in a background of CCH. In fact, all 
patients with hereditary MTC virtually presented CCH (Leboulleux et al., 2004). 
There are two different types of CCH: physiologic or reactive, where the number of follicles 
with one or more C-cells is increased, associated with inflammatory and metabolic disorders 
and classically with a chronic lymphocytic thyroiditis, and nodular or neoplastic, 
characterized by an increased number of C-cells aggregates, frequent in tumors. Physiologic 
CCH cannot be recognized with certainty on routine histological sections and has to be 
diagnosed with the help of immunostains. On the other hand, nodular or neoplastic CCH 
can be identified with conventional histological sections because the C-cells are large, mildly 
to moderately atypical and cytologically indistinguishable from those of invasive MTC, 
resulting in a partial or complete replacement of the follicle (Albores-Saavedra & Krueger, 
2001; Perry et al., 1996).  
1.1.1 Hereditary MTC syndrome 
Hereditary MTC syndrome (MEN2 – multiple endocrine neoplasia type 2 or Sipple’s 
syndrome) is an autosomal disorder characterized by activating germline mutations of the 
RET proto-oncogene, with a prevalence of 1:30,000 subjects (Brandi et al., 2001).  It is divided 
in three clinical variants: a) MEN2A (medullary thyroid cancer, mono- or bilateral 
pheochromocytoma, primary hyperparathyroidism and cutaneous lichen amyloidosis); b) 
familial medullary thyroid cancer (FMTC); c) MEN2B (medullary thyroid cancer, mono- or 
bilateral pheochromocytoma, mucosal and intestinal ganglioneuromatosis, marfanoid 
habitus) (Brandi et al., 2001; Raue & Frank-Raue, 2007). Although these variants have MTC 
as a common denominator, they differ for the aggressiveness of this cancer, in a decreasing 
order MEN2B>MEN2A>FMTC (Raue & Frank-Raue, 2007).  
In patients with FMTC, MTC is the only clinical manifestation. According to the 
“International RET Mutation Consostium”, to make the diagnosis of FMTC is required the 
onset of MTC in at least four family members (Mulligan et al., 1995). 
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Patients affected with hereditary MTC syndrome initially develop CCH that then progresses 
to early invasive medullary microcarcinoma, and eventually develop invasive macroscopic 
MTC (ATA Guidelines Task Force et al., 2009). 
MEN2 has a genotype-phenotype correlation. In fact, an association between specific 
mutations of the RET gene and the age at onset, the aggressiveness of MTC and the presence 
of other endocrine disorders is well documented. The RET mutation screening allows to 
stratify the risk in three levels, depending on the mutated codon. The specifically mutated 
RET codons correlate with the MEN2 variant, with the age at onset and the aggressiveness 
of thyroid cancer. MTC generally occurs in the first year of age in subjects with MEN2B, 
between 5 and 25 years in subjects with MEN2A and later in subjects with FMTC. In patients 
with MEN2, the therapeutic approach is correlated to the clinical subtype and to the 
mutation, according to the risk levels (Brandi et al., 2001) (Table 1).  
 
Risk level Domain Codons MEN2 variant 
    
1 (Low) Extracellular 609 MEN2A 
 Intracellular 768, 790, 791, 804 FMTC 
 Intracellular 891 MEN2A 
    
2 (High) Extracellular 611, 618, 620, 630, 634 MEN2A 
    
3 (Very high) Intracellular 883, 918, 922 MEN2B 
    
Table 1. Risk levels in MEN2 syndrome. 
Subjects with the highest risk level (3) have the most aggressive MTC and should have 
thyroidectomy with a central node dissection within the first six months of life and 
preferably within the first month of life. In subjects classified as risk 2 level, thyroidectomy 
with removal of the posterior capsule should be performed before the age of five years. For 
subjects with the lowest risk level (1) at this moment there are differing opinions on when 
thyroidectomy should be performed. According to some authors, in fact, total 
thyroidectomy with lymph node dissection of the central compartment should be practiced 
within the fifth year of life, according to others such intervention should be performed later, 
but within the tenth year of life. Other authors finally suggest to periodically perform the 
pentagastrin stimulation test for calcitonin and to perform the surgery at the first positive 
test. In all cases, if a pheochromocytoma is present, total thyroidectomy should be 
performed after surrenectomy to avoid a catecholaminergic crisis during the surgery 
(Brandi et al., 2001).        
1.2 Diagnosis of MTC in patients with the suspicion of MTC 
Thyroid tumors are the most common endocrine neoplasms. Most of thyroid nodules are 
benign but in the 5-10% of cases they are carcinomas. MTC occurs in less than 1% of thyroid 
nodules and accounts for 5-10% of thyroid malignancies (Schlumberger et al., 2003). 
Sporadic MTC can arise clinically at any age but its incidence peaks during the fourth and 
sixth decades of life (Leboulleux et al., 2004). 
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The suspicion of MTC  arises in a patient with one or more thyroid nodules associated with 
elevated basal calcitonin levels (> 10 pg/ml), with or without a familial history of MTC.  
In the presence of a thyroid nodule, several clinical features may prompt to suspect a MTC: 
its location in the upper third of the thyroid lobe, pain during the thyroid palpation, a 
diarrhoeal syndrome and flushing that are more frequent in patients with a large tumor 
burden. At the ultrasonography, MTC usually appears as a hypoechogenic solid nodule 
with frequent microcalcifications, with or without lymph node abnormalities (Leboulleux et 
al., 2004). 
High serum calcitonin levels are physiological in neonates, followed by an age-related 
decline from birth to about 1 year of age (Leboulleux et al., 2004). Elevated basal serum 
calcitonin levels are found in subjects with CCH or MTC. Anyway, in some cases it is 
possible to observe false positive for high serum calcitonin levels in adult individuals. 
Conditions related to high calcitonin levels are: severe chronic renal failure and dialysis, 
chronic hypercalcemia, therapies with proton-pump inhibitors or other drugs, chronic 
hypergastrinemia, pernicious anemia, hepatic cirrhosis, auto-immune thyroid disorders or 
follicular tumor, hyperthyroidism, hyperparathyroidism and pseudo-
hypoparathyroidism, systemic inflammatory state, pregnancy and lactation. Furthermore, 
calcitonin assays can be falsely positive because of interference with circulating 
heterophilic antibodies binding (Leboulleux et al., 2004; Pacini et al., 2010). Calcitonin 
levels are also correlated with age and BMI (especially in men) and cigarette smoking can 
increase the plasma concentration of calcitonin (van Veelen et al., 2009) (Table 2). False 
negative for calcitonin serum concentrations are also possible and are related to the “hook 
effect” (Leboeuf et al., 2006). 
 
Non-thyroid diseases Thyroid diseases Drugs 
Physiological 
conditions 
Hypergastrinemia 
Auto-immune 
thyroiditis 
Proton-pump 
inhibitors 
Age 
Hyperparathyroidism Hyperthyroidism 
Glucocorticoid
s 
BMI 
Pseudohypoparathyroidism 
Thyroid 
carcinoma 
Beta-blockers Sex 
Chronic renal failure  Glucagon 
Physical 
activity 
Pernicious anemia   Pregnancy 
Hepatic cirrhosis  Smoking Lactation 
Inflammatory state    
Neuroendocrine tumors    
Pheochromocytoma    
Paraganglioma    
Breast cancer    
Enteropancreatic tumors    
Small cell lung carcinoma    
Table 2. Conditions associated to high serum calcitonin levels independently  of medullary 
thyroid carcinoma. 
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MTC may also express a number of genes usually not expressed or expressed at low levels 
in the normal C-cells. The protein products of these genes include somatostatin, pro-
opiomelanocortin, vasointestinal active peptide, serotonin, prostaglandins and others and 
they can produce clinical syndromes including Cushing’s disease, flushing or diarrhoea. 
Chromogranin-A levels may also be elevated in the presence of large metastases 
(Leboulleux et al., 2004). 
Diagnosis of MTC is based on typical histological characteristics (tumor cells arranged in 
trabecular, insular or sheet-like patterns with or without stromal amyloid deposits) and 
immunohistochemical findings (positive staining for calcitonin, CEA and chromogranin and 
negative staining for thyroglobulin) (Costante et al., 2007). Anyway, pentagastrin 
stimulation test, immunocytochemistry for calcitonin and calcitonin measurement in wash-
out fluid from fine-needle aspiration of thyroid nodules are suggestive. 
The primary treatment of both hereditary and sporadic MTC is total thyroidectomy with 
lymph node dissection, with the intention of remove all neoplastic tissue present in the neck. 
Surgery should be performed after careful exclusion of pheochromocytoma (Leboulleux et 
al., 2004). Classification of MTC is based on the pathological tumor node metastases (TNM) 
system (Table 3). 
 
T (primary tumor) Tx: Primay tumor cannot be assessed 
 T0: No evidence of primary tumor 
 
T1:  Tumor size ≤ 2 cm and no growth out of the 
thyroid  
 
T1a: Tumor size < 1 cm and no growth out of the 
thyroid 
 
T1b: Tumor size between 1 and 2 cm and no growth 
out of the thyroid 
 
T2: Tumor size between 2 and 4 cm and no growth out 
of the thyroid 
 
T3: Tumor size ≥ 4 cm or small growth out of the 
thyroid 
 
T4a: Tumor of any size with extensive growth beyond 
the thyroid gland into nearby tissues of the neck 
(Moderately advanced disease) 
 
T4b: Tumor of any size with either back toward the 
spine or into nearby large blood vessels (Very 
advanced disease) 
N (regional lymph node 
metastases) 
Nx: Regional lymph nodes cannot be assessed 
 N0: No evidence of regional lymph nodes 
 N1:  The cancer has spread to nearby lymph nodes 
 
N1a: The cancer has spread to lymph nodes around the 
thyroid 
 
N1b: The cancer has spread to other lymph nodes in 
the neck or behind the throat or in the upper chest  
M (distant metastases) Mx: Distant metastases cannot be assessed 
 M0: No evidence of distant metastases 
 M1: Evidence of distant metastases 
Table 3. TNM system for medullary thyroid cancer (MTC). 
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A diagnosis of MTC in an early and therefore potentially surgically eradicable and higher 
curable stage of disease is essential to improve the prognosis of this tumor (Pacini et al., 
1994). 
In patients with non-metastatic MTC, survival rates amount about 78-100% at 5-year and 
75% at 10-year, respectively. Survival rates strongly decrease in case of metastatic disease 
and amount about 24% at 5-year and 10% at 10-year respectively (Kapiteijn et al., 2011).  
1.3 Usefulness of pentagastrin stimulation test for diagnosis of MTC and differential 
diagnosis between subjects affected by C-cells proliferation and normal subjects and 
between CCH and MTC 
Pentagastrin stimulation test for calcitonin is the most widely used test for calcitonin 
secretion, useful to distinguish normal C-cells from pathological C-cells (Leboulleux et al., 
2004; Milone et al., 2010; Pacini et al., 2010). This test is performed in case of borderline 
serum calcitonin levels or in case of high serum calcitonin levels but less than 100 pg/ml. 
After overnight fasting, basal serum calcitonin is measured and then the patient receives a 
slow intravenous injection of 0.5 μg pentagastrin per Kg body weight and calcitonin is 
measured again 3 and 5 minutes after the injection. 
Serum calcitonin concentrations are helpful in the early detection of C-cells disease but it is 
still unclear whether they can be used also for the preoperative differential diagnosis 
between CCH and MTC on the basis of the calcitonin peak after pentagastrin stimulation 
test. Few studies have been performed to preoperatively discriminate between CCH and 
MTC but they show high variability in the calcitonin cut-offs after pentagastrin test to 
discriminate between CCH and MTC. A calcitonin cut-off after pentagastrin stimulation test 
corresponding to about 300 pg/ml seems to be highly predictive in preoperatively 
distinguishing CCH from MTC (Figure 2). In the clinical practice, this finding may need to 
perform surgery in patients with calcitonin levels higher than these after pentagastrin 
stimulation test and to submit a periodical re-evaluation with the stimulation test and neck 
ultrasonography in those patients with calcitonin levels between about 100 and 300 pg/ml 
(Milone et al., 2010). 
The pentagastrin stimulation test is contraindicated during pregnancy and in patients with 
asthma, coronary disease, severe hypertension or duodenal ulcer. Side-effects include 
dizziness, tachycardia/bradycardia, nausea and substernal tightness (Leboulleux et al., 
2004; Pacini et al., 2010).  
1.4 Differential diagnosis between CCH/MTC and ectopic calcitonin secretion 
In about 15% of cases high levels of calcitonin are associated to ectopic production by 
tumors. Neuroendocrine tumors arising from gastro-entero-pancreatic tract (gastrinoma, 
VIPoma, insulinoma, etc.), respiratory tract (lung, bronchus), breast , medulla of adrenal 
gland and paraganglia may be associated with elevated serum calcitonin levels, even in 
cases where there is a negative immunohistochemistry reaction for calcitonin (Pacini et al., 
2010; Toledo et al., 2009) (Table 2).  
Considering false positive causes of increased serum calcitonin levels and the above 
mentioned tumors associated with ectopic secretion of this marker, it is not surprising that 
hypercalcitoninemia  could result sometimes in erroneous recommendations of total 
thyroidectomy. Therefore, in order to avoid misdiagnosis and unnecessary thyroid surgery, it 
is mandatory to conduct correct investigations in cases with  elevated basal serum calcitonin 
levels in order to rule out possible diagnosis different from MTC (Toledo et al., 2009). 
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Fig. 2. Calcitonin peak after pentagastrin stimulation test performed before surgery to 
preoperatively distinguish C cell hyperplasia (CCH) and medullary thyroid cancer (MTC) 
(from Milone et al., 2010). 
1.5 Usefulness of fine-needle cytology (FNC) to preoperatively recognize a MTC 
Fine-needle aspiration cytology (FNC) represents the main tool in the diagnostic evaluation 
of thyroid nodules, but it is not frequently proposed as a routine procedure in patients with 
high serum calcitonin levels, due to its low specificity and sensitivity (Boi et al., 2007). 
Routine measurement of calcitonin in nodular thyroid disease is a specific and sensitive 
method to improve the early preoperative diagnosis of unsuspected sporadic MTC with 
better accuracy than routine FNC. Serum calcitonin is also more sensitive than FNC in the 
pre-operative diagnosis of MTC (Elisei et al., 2004). Serum calcitonin is the most sensitive 
and accurate diagnostic tool for MTC, but it is not helpful to localize primary tumor in the 
thyroid and its neck recurrence or metastases in patients submitted to thyroidectomy (Boi et 
al., 2007). Immunohistochemistry with anti-calcitonin antibodies improves the diagnostic 
sensitivity of FNC. Anyway, this procedure is only performed when there is a strong 
suspicion of MTC and not on routine basis. On this basis, serum calcitonin should be 
measured routinely in the clinical work-up of thyroid nodules, followed by a pentagastrin 
stimulation test in all cases of detectable basal calcitonin levels (Elisei et al., 2004). Increasing 
the diagnostic accuracy could help the surgeon to perform more radical treatment of MTC, 
thus achieving frequent normalization of postoperative serum calcitonin levels. Anyway, 
whether this results indicates definitive cure remains to be established on the basis of longer 
follow-up (Pacini et al., 1994).  
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Assaying calcitonin in the wash-out fluid and immunohistochemistry for calcitonin from 
FNC under ultrasonographic guidance could be useful in the preoperative diagnosis of 
MTC. 
There are several studies that aimed to evaluate the usefulness of calcitonin assay in the 
wash-out from FNC, alone or combined with cytology in the pre-surgical evaluation of MTC 
patients with thyroid nodules. Anyway, although elevated serum calcitonin levels, basal 
and after pentagastrin stimulation test, strongly suggest the presence of MTC, no study 
showed a statistical correlation between serum calcitonin levels and calcitonin levels in the 
wash-out fluid from FNC.  
Calcitonin assay in the wash-out from FNC seems to be a highly reliable diagnostic 
procedure to identify primary tumor and recurrent or metastatic MTC (Boi et al., 2007). 
1.6 Diagnosis of MTC persistence/relapse after surgery 
The definitive cure of MTC is strongly dependent on the completeness of the first surgical 
treatment. If tumor tissue is not totally removed, the subsequent surgeries are not as 
effective as a complete primary surgery in achieving the disease remission. Anyway, the 
clinical, biochemical and radiological criteria to establish how extended has to be the 
surgical act to completely abrogate the risk of relapse are not clear.  
For node-positive thyroid cancers, compartment-oriented microdissection is the gold 
standard of care, whereas the concept of prophylactic lymph-node dissection continues to 
arouse controversy. Most studies agree that routine lymph-node dissection is unnecessary 
for low-risk well-differentiated thyroid cancer. Because occult lymph-node metastases are 
frequent in high-risk MTC, compartment-oriented microdissection helps prevent 
reoperations for recurrences arising from residual nodes, sparing patients the excess 
morbidity from reoperations in the neck (Dralle & Machens, 2008). 
Total thyroidectomy and central neck dissection is recommended for all patients with MTC, 
but the indication for lateral neck dissection is still controversial and there is not a standard 
approach to neck surgery. The total number of lymph node metastases is predictive for 
biological remission after surgery. Because of the same frequency in the ipsilateral, 
controlateral and central compartments involvement in either sporadic or hereditary MTC, 
Scollo et al. suggested performing a central and bilateral neck dissection in all patients with 
MTC. A bilateral neck dissection may be avoided in patients with unilateral tumor 
involvement of the thyroid only when no involvement of the ipsilateral and central neck 
compartment is found (Scollo et al., 2003). 
Intraoperative calcitonin monitoring seems to be a predictor of the final outcome after 
surgery in patients with MTC. A  calcitonin decrease greater than 50% 30 minutes after 
surgery is associated with a complete tumor removal while a decrease of calcitonin less than 
50% 30 minutes after surgery indicates an incomplete tumor removal and suggests to extend 
the surgery on other lymph node compartments (Faggiano et al., 2010) (Figure 3). 
In comparison to the differentiated thyroid carcinoma, MTC is more difficult to treat and 
has higher rates of recurrence and mortality. Unlike differentiated carcinoma, there is no 
known effective systemic therapy since MTC cells do not concentrate radioactive iodine and 
MTC does not respond well to external radiotherapy or conventional chemotherapy 
(Czepczyński et al., 2007). 
Prognostic factors (relevant) to predict outcome in MTC include: age at diagnosis, gender, 
initial extent of the disease, such as lymph node and distant metastases, tumor size, extra-
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thyroid invasion, vascular invasion, calcitonin immunoreactivity, amyloid staining and Ki-
67 score in tumor tissue, postoperative gross residual disease, and postoperative plasma 
calcitonin levels (Schlumberger et al., 2003) (Table 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Correlation between percentage calcitonin decrease 30 minutes after surgery and 
post-surgical outcome in patients undergone surgery for medullary thyroid cancer (from 
Faggiano et al., 2010). 
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Age Patients aged over 50-60 years fare worse 
  
Sex The male sex has been associated with a worse prognosis 
  
Stage of MTC This is the most important prognostic factor. 
The presence of lymph node and distant metastases at presentation is 
associated with a worse prognosis with poor survival 
  
Genetics In a decreasing order, the aggressiveness of hereditary medullary 
thyroid cancer is MEN2B>MEN2A>FMTC. MTC of the MEN2A 
variety is associated with a better prognosis than the sporadic variety 
  
Size Small tumors <1 cm are associated with a better prognosis 
  
Biochemical cure It predicts a good survival 
  
Histological 
features 
High mitotic count (> 1 per 25 high-power field), high Ki-67%, small-
cell variant, necrosis, absence of amyloid are associated with a worse 
prognosis 
Table 4. Prognostic factors to predict outcome in patients with medullary thyroid carcinoma 
(MTC). 
In patients with MTC a long-term biochemical monitoring including serum calcitonin and 
CEA measurements is mandatory (ATA Guidelines Task Force et al., 2009). 
Postoperative unsuppressed calcitonin and CEA concentrations may persist elevated during 
2-3 months after surgery due to their long half-life in the blood, while increasing calcitonin 
and CEA serum levels after this time indicate disease persistence and progression 
(Leboulleux et al., 2004; Pacini et al., 2010; Faggiano et al., 2009). Undetectable basal serum 
calcitonin levels, further confirmed after a pentagastrin stimulation test, are a strong 
predictor of complete remission (Pacini et al., 2010).  
In patients with postoperative persistent calcitonin levels the use of imaging techniques is 
mandatory for diagnostic purposes and therapy decision. Anyway, the detection of tumor 
foci is often not achieved with conventional imaging techniques (neck ultrasonography, CT-
scan, MRI, bone scintigraphy). Postoperative calcitonin concentrations less than 500 pg/ml 
usually indicate a small residual disease in the neck or mediastinal lymph nodes, not easily 
detectable. The evaluation of the clinico-biological and immunohistochemical tumor profile 
may be used in order to select the best imagine technique to be performed in patients with 
postoperative persistent or relapsing MTC. In particular, FDG-PET seems to correlate to 
tumor proliferation index Ki-67% and to be able to detect metastases in patients with 
postoperative persistent MTC when conventional imaging techniques are negative 
(Faggiano et al., 2009) (Figure 4). 
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Fig. 4. Lymph node metastases in a patient with postoperative persistence of medullary thyroid 
carcinoma (MTC) positive at FDG-PET (B) and negative at conventional imaging techniques 
(CT-scan [A], Octreoscan [C] and MIBG-scintigraphy [D]) (from Faggiano et al., 2009). 
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For advanced MTC, conventional oncological therapies (radiotherapy and systemic 
chemotherapy) have scarce effectiveness. For patients with MTC unresponsive to 
conventional treatments, novel therapies are needed to improve disease outcomes. As a 
result of the increasing knowledge on the biological basis of MTC, therapeutic agents that 
target specific molecular pathways have been developed (Kapiteijn et al., 2011). Multiple 
novel therapies primarily targeting angiogenesis have entered clinical trials for metastatic 
thyroid carcinoma (including MTC). Partial response rates up to 30% have been reported, 
but prolonged disease stabilization is more commonly observed. The most successful agents 
are those targeting the vascular endothelial growth factor receptors (VEGFRs) (Sherman, 
2011).  Monotarget kinase inhibitors and multikinase inhibitors could represent the best 
therapeutic option to manage patients with advanced MTC (Kapiteijn et al., 2011). 
2. Conclusions 
Medullary thyroid carcinoma is a secretive neuroendocrine tumor originating from thyroid 
C-cells. This tumor is, after the anaplastic carcinoma, the most aggressive thyroid 
malignancy with high morbidity and mortality. The prognosis of MTC strongly depends on 
early diagnosis and the completeness of the first surgical treatment. In case of lymph node 
involvement at the time of the diagnosis, the outcome is poorer because of a very high rate 
of disease persistence or relapse after surgery.  
Treatment for patients with metastatic or advanced MTC has to taken in account novel 
agents targeting specific molecular pathways and resulting in arrest of tumor growth. 
Future efforts should be directed to develop diagnostic and therapeutic algorithms to obtain 
as early as possible the identification of tumor onset and to differentiate MTC from CCH, 
ensuring high rates of cure and long-time disease free survival. Further studies are required 
to improve knowledge of CCH and MTC, to detect new hereditary MTC-causing mutations 
and develop new diagnostic procedures and therapeutic strategies. 
Finally, to optimize the management of patients with MTC, a multidisciplinary team of all 
the different specialists involved in MTC diagnosis and therapy is highly recommended. 
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